How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Implantable Depot for Slow Drug Release

Organization name

ascenion GmbH

Profile

Challenge

After surgical removal of solid tumours, infiltrating cells from the tumour’s marginal zone often develop to centres of secondary tumour with relapse rates strongly depending on the tumour tissues. Treatment with cytostatics is the state of the art therapy for prevention of secondary tumour progression, usually with severe side effects for the patients. The clinical need for improved secondary tumour suppression is therefore high.

Technology

An implantable agent consisting of liquid crystalline cubic phases that allows constant and slow release of two pharmaceutically effective substances, like Carboplatin and Paclitaxel, with different kinetics. Local embedding of the matrix into tumour areas after surgery provides high effective drug concentrations at the required place of action, thereby reducing side effects and long-time dosing of the drug usually required in systemic application.

Commercial Opportunity

Exclusive in-licensing opportunity for clinical development and application

Developmental Status

Pre-clinical mouse data show an increased survival upon drug application. Release and diffusion kinetics of the drugs as well as tumour growth reduction upon treatment were detected. In a prospective clinical study on feasibility, safety and short-term effects in glioblastoma patients with a Paclitaxel/Carboplatin depot, the differential release kinetic of both drugs was observed. Side effects like brain edema observed depend on drug concentrations in the matrix.

Patent Situation

Granted European Patent (EP 1204407, validated in AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, NL, SE) and US patent (7,556,827), and pending applications in Canada (2,378,401) and Japan (2003-506397).

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries